These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 11303744)
21. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218 [TBL] [Abstract][Full Text] [Related]
22. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study. Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625 [TBL] [Abstract][Full Text] [Related]
23. The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2. Campolo M; Casili G; Biundo F; Crupi R; Cordaro M; Cuzzocrea S; Esposito E Antioxid Redox Signal; 2017 Sep; 27(8):453-471. PubMed ID: 28006954 [TBL] [Abstract][Full Text] [Related]
24. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274 [TBL] [Abstract][Full Text] [Related]
25. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Zou L; Xu J; Jankovic J; He Y; Appel SH; Le W Neurosci Lett; 2000 Mar; 281(2-3):167-70. PubMed ID: 10704769 [TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system. Guo Z; Xu S; Du N; Liu J; Huang Y; Han M Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716 [TBL] [Abstract][Full Text] [Related]
27. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Prediger RD; Aguiar AS; Rojas-Mayorquin AE; Figueiredo CP; Matheus FC; Ginestet L; Chevarin C; Bel ED; Mongeau R; Hamon M; Lanfumey L; Raisman-Vozari R Neurotox Res; 2010 Feb; 17(2):114-29. PubMed ID: 19629612 [TBL] [Abstract][Full Text] [Related]
28. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135 [TBL] [Abstract][Full Text] [Related]
29. Rotenone increases glutamate-induced dopamine release but does not affect hydroxyl-free radical formation in rat striatum. Leng A; Feldon J; Ferger B Synapse; 2003 Dec; 50(3):240-50. PubMed ID: 14515342 [TBL] [Abstract][Full Text] [Related]
30. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Rozas G; Liste I; Guerra MJ; Labandeira-Garcia JL Neurosci Lett; 1998 Apr; 245(3):151-4. PubMed ID: 9605478 [TBL] [Abstract][Full Text] [Related]
31. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Mandel S; Grünblatt E; Maor G; Youdim MB Neurochem Res; 2002 Oct; 27(10):1231-43. PubMed ID: 12462421 [TBL] [Abstract][Full Text] [Related]
32. Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion. Oeckl P; Scheffold A; Lechel A; Rudolph KL; Ferger B Neuroreport; 2014 Mar; 25(5):335-9. PubMed ID: 24525820 [TBL] [Abstract][Full Text] [Related]
33. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
34. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease. Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118 [TBL] [Abstract][Full Text] [Related]
35. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485 [TBL] [Abstract][Full Text] [Related]
36. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381 [TBL] [Abstract][Full Text] [Related]
37. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. Saporito MS; Brown EM; Miller MS; Carswell S J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541 [TBL] [Abstract][Full Text] [Related]